openPR Logo
Press release

Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Conference

04-13-2022 04:04 PM CET | Health & Medicine

Press release from: SMi Group

P-375 PR4

P-375 PR4

SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference

The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation.

Industry leaders will uncover the latest advancements in the field, highlighting the use of opioids and the future for cannabinoids within the pain therapeutics field. Furthermore, policy experts will provide an essential regulatory perspective for this year's agenda, providing an exciting and comprehensive insight into the pain therapeutics market.

Register your place online at:

In recent news, AOBiome's B244 demonstrated positive results from its Phase 2b trial for both Pruritus (Itch) and Appearance of Atopic Dermatitis (Eczema). AOBiome Therapeutics, a clinical stage biotechnology company focused on transforming human health by developing topical biologic therapies for systemic inflammatory conditions, announced positive pivotal Phase 2b results from its trial evaluating B244 in both pruritus (itch) and appearance of atopic dermatitis (eczema).

The trial enrolled 547 patients with mild-to-moderate appearance of atopic dermatitis and moderate-to-severe itch. The trial met all primary and secondary endpoints, showing that B244 significantly reduced itch, reduced overall disease severity, improved skin clearance, and improved health-related quality of life measures at 4 weeks compared to placebo.

Their findings:
•B244 reduced patients' WI-NRS score by an average of 34.3% and achieved clinically meaningful 4-point itch response
•Lesional severity (appearance) improved for IGA and EASI
•Results were achieved in 4 weeks
•Safe and well tolerated with no SAEs and no single adverse event occurred in greater than 1% of the active group.

SMi Group are delighted to announce that Todd Krueger, President and CEO from AOBiome will be presenting on day 1 of the Pain Therapeutics Conference 2022 on AOBiome's Drug Development Program for the Treatment of Pruritus associated with Atopic Dermatitis which will cover:
•An introduction to Atopic Dermatitis and Pruritus
•Discussion of mechanisms and pre-clinical development work
•Review of clinical results and the challenges faced
•The future outlook for this research

SMi Group also caught up with Todd Krueger, President and CEO, AOBiome for an exclusive speaker interview to discuss his role, breakthroughs, challenges and upcoming projects.

To download your complimentary copy, please visit:
SMi Group offer direct access to key decision makers through tailored sponsorship and exhibitor packages. For details contact Andrew Gibbons on +44 (0)20 7827 6156 or email at

SMi's 22nd Annual Pain Therapeutics Conference
4th - 5th May 2022
London, UK

India House, 45 Curlew Street

--- ENDS -

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Conference here

News-ID: 2602460 • Views: 279

More Releases from SMi Group

Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK. With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022. With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week. With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman. The
Assessing device development and regulation for advanced innovation
Pre Filled Syringes West Coast USA Conference 2022 Launches Assessing device development and regulation for advanced innovation SMi's 6th Annual Conference Pre-Filled Syringes West Coast June 13 - 14, 2022 | San Diego, CA, USA SMi is delighted to announce the 6th annual Pre-Filled Syringes West Coast conference, to be held in San Diego. As part of SMi's leading series of drug delivery device conferences, the 2022 event will provide insights into the rapidly

All 5 Releases

More Releases for PR4

Due to COVID-19, Pain Therapeutics Conference will be accessed remotely
SMi Group reports: Pain Therapeutics conference will reconvene on 11th and 12 May by remote access. Regarding concerns over COVID-19 SMi's 20th Annual Pain Therapeutics conference will return on the 11th and 12th May 2020 via remote access only. The two-day conference will provide delegates the chance to explore all areas of pain therapeutics, such as pain treatment highlighting clinical success to date as well as evaluating the potential of
10 Key Reasons to attend SMi’s 2nd Annual Pharmaceutical Microbiology East Coa …
In just 3 weeks, the highly anticipated Pharmaceutical Microbiology East Coast conference and exhibition will take place in Boston, USA, on April 10 and 11, 2019. SMi Group are delighted to share 10 key reasons to why you should attend the this event in Boston, next month. This year’s agenda features a series of presentations from industry experts to discuss the key topics in the pharmaceutical microbiology industry such as risk
Exclusive insights into the latest innovations at Drug Discovery Chemistry
SMi Reports: Gain the latest insights into the drug discovery field at the 3rd annual conference on Drug Discovery Chemistry , next month in London. Last month, personal invitations from our conference chairman Roderick E. Hubbard at Vernalis Research were sent inviting interested parties to attend the 3rd Annual Drug Discovery Chemistry Conference, taking place on the 18th and 19th March 2019 in London at the Copthorne Tara Hotel. The
SMi’s 3rd Annual 3D Cell Culture Conference takes place in only 2 weeks
SMi is proud to announce the 3rd Annual 3D Cell Culture conference is returning to London in just under two weeks’ time. Researchers globally are realizing the potential of 3D cell culture for various applications, including testing and discovering new drugs to treat cancer, organ-on-chip models to study the human physiology in an organ specific context, and 3D cell printing to produce organ models. Therefore, this market is likely to
Pharmaceutical Microbiology UK CONFEX takes place in less than a week!
SMi reports: Registration will close in less than week, as the countdown begins for the 8th Annual Pharmaceutical Microbiology UK Conference. The 8th Annual Pharmaceutical Microbiology UK, will take place at the contemporary Coprthorne Tara Hotel in London, on 21 and 22 January 2019. With less than a week remaining, both the pharmaceutical and specialty chemicals industries currently facing both unparalleled opportunities and challenges will gather to address the key
Exclusive interviews released from #milsocialmedia speakers US Army and Canadian …
SMi Group caught up with two speakers for the 8th annual Social Media in the Defence & Military Sector, Ms Lucy Ellis, Communications Advisor at Canadian Department of National Defense and Mr Anthony O'Bryant, Deputy Army Digital Media Division at US Army, to get an insight on their expert point of view. Here is a snippet from their interviews: Anthony O'Bryant, Deputy Army Digital Media Division, US Army Tell us about you